B16-F10: A Murine Melanoma Model

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common.  Of all the skin cancer types, melanoma is a serious form of skin […]

Modeling Liver Cancer with Syngeneic Hepa 1-6: An Update

Hepatocellular carcinoma (HCC) affects over one million people globally and is currently the third leading cause of cancer related deaths in the world.[1] Worldwide, there are 800,000 new diagnoses and 700,000 patient deaths each year. The incidence of HCC is highest in Southeast Asia and Sub-Saharan Africa due to high prevalence of hepatitis B and C […]

LL/2: An Immunosuppressive Murine Tumor Model

Lung cancer is the second most common cancer diagnosed in both men and women in the United States and is, by far, the most common cause of cancer-related deaths in men and women. In 2019, the American Cancer Society estimates that 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) will […]

PyMT – A Transplantable Murine Model of Breast Cancer

Breast cancer remains one of the most prolific and life-threatening diseases among women worldwide. According to the American Cancer Society, among US women in 2017, there were approximately 253,000 new cases of invasive breast cancer resulting in 41,000 deaths.[1] Approximately 6-10% of new breast cancer cases (15,000-25,000) are diagnosed as metastatic (Stage IV). However, it […]

Pan02: A Murine Model of Pancreatic Cancer

Pancreatic cancer is the ninth most commonly diagnosed cancer and ranks as one of the deadliest with the lowest 5-year survival rate of 5-8%.[1,2,3] This year alone, the American Cancer Society estimates that 56,770 people will be diagnosed with the disease of which more than 45,750 people may not survive. Pancreatic ductal adenocarcinoma (PDAC) being […]

Prostate Cancer Modeling with PC-3: One Model, Four Applications

Prostate cancer is the second most common type of cancer in men, with 1 in 9 men being diagnosed in their lifetime at a mean age of 66. In 2019, prostate cancer is estimated to have 174,650 new diagnoses and 31,620 patient deaths. Prognoses are very good for patients in which disease is detected early, with […]

MB49 – A Bladder Cancer Murine Tumor Model

Bladder cancer is one of the most frequent cancers of the urinary tract, accounting for about 80,000 new cases and 18,000 deaths in the United States in 2018, according to the National Cancer Society. Typically, patients with bladder cancer have limited surgical or treatment options. Traditional chemotherapeutics are ineffective, and surgery is often used to […]

TIGIT Directed Human Antibody Modulates T-regulatory and Effector Cell Function

MI Bioresearch was mentioned within in the Seattle Genentics poster they presented at the AACR 2019 Conference. Stated under the “SGN-TIGIT displays strong anti-tumor efficacy” figures: “SGN-TIGIT treatment in CT26 and A20 syngeneic models cured 50% and 33% of animals, respectively. SGN-TIGIT in the MC38, E0771, EMT6, and an alternative […]

Radiation Response in Preclinical Orthotopic Models of Brain Cancer

Introduction and Background Glioblastoma multiforme (GBM) is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. It is the most common primary brain tumor. The American Cancer Society estimates that in 2019 there will be >23,000 new cases diagnosed and >17,000 […]

MC38: An Immunoresponsive Murine Tumor Model

Colorectal cancer is the fourth most common cancer diagnosed in the United States. Colorectal cancer represents the third leading cause of cancer-related deaths in women and the second in men. In 2019, over 145,000 estimated new cases of colorectal cancer in the United States will be diagnosed and more than 51,000 patient deaths will occur. […]

C1498-Luc-mCherry: A Syngeneic Acute Myeloid Leukemia (AML) Model

Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults with a 5-year survival rate of ~25% following diagnosis.[1] While two-thirds of AML patients treated with standard high dose chemotherapy achieve remission, 50% of patients relapse after remission. The majority of relapses occur within two to three years of initial treatment, and every […]

Syngeneic Model for Preclinical Evaluation of Ovarian Cancer

Ovarian cancer is considered a relatively rare gynecologic malignancy but has one of the highest mortality rates due to the non-specific symptoms that occur in early stage disease. This results in most women being diagnosed with advanced stage disease. The incidence of ovarian cancer within the United States is approximately 22,000 cases per year and […]

Subcutaneous and Systemic Preclinical Modeling of A20 Murine B Cell Lymphoma

Lymphomas represent a set of lymphoid cell malignancies that can range from indolent to aggressive. B cell-derived lymphomas, specifically non-Hodgkin lymphoma (NHL), are the most prevalent, but this disease can also originate from T cells. In 2018, an estimated 74,680 new cases of NHL in the United States will be diagnosed, and 19,910 patient deaths […]

Hepa 1-6: A Murine Model of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is an aggressive malignancy which has gradually increased in incidence to affect one million people worldwide and is currently the third leading cause of cancer related deaths in the world.[1,2] The prevalence of HCC is highest in Asia and Africa due to high endemicity of hepatitis B and C viruses which strongly […]

HCC70: A Model of Triple Negative Breast Cancer

Table 1: Endpoint Analysis Following Treatment with Paclitaxel and Focal Radiation Group # Treatment Related Weight Change Median % ΔT/ΔC (day 63) % Regression (day 63) % Complete Regression % Partial Regression % Tumor Free Survivors Vehicle 4.8 100 0 0 0 0 Paclitaxel 4.4 72.2 0 0 0 0 […]

E0771 Syngeneic Breast Cancer Model

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer lacking estrogen receptor, progesterone receptor, and HER2 amplifications; making it difficult to target therapeutically. Consequently, there’s a constant demand for better treatment options for TNBC. To help address the need for TNBC models, we highlighted the EMT6 model last month and […]

EMT-6 Syngeneic Breast Tumor Model – A Powerful Tool for Immuno-Oncology Studies

Breast cancer is the most common cancer among women in the United States and is the fourth leading cause of cancer death. In 2017, an estimated 252,710 new cases were diagnosed (15% of all new cancers) and 40,610 patient deaths occurred. Early detection initiatives together with improved treatment options have resulted in increases in the […]

High-Throughput Analysis of MAPK and JAK-STAT Signaling in CT26 Tumors Using a Combination of Immunophenotyping and Phospho-Flow Cytometry

Introduction and Background The development of robust platforms that enable phospho-protein-based analysis of cell signaling in the tumor microenvironment is pivotal for small molecule drug development. Currently lacking are reliable applications that can simultaneously measure multiple phospho-proteins in both tumor cells and immune cells ex vivo. This can be crucial […]

Evaluation of Immunomodulatory Agents in Classically Immunologically “Cold” Cancers Using Syngeneic Mouse Models of Breast and Ovarian Cancer

Introduction and Background T cell checkpoint inhibitors have demonstrated significant clinical benefit in immunologically “hot” cancer types like melanoma, kidney, bladder and lung cancers. “Hot” tumors are characterized by a significant CD8+ T cell infiltrate and high neoantigen burden. Breast cancer is regarded as an immunologically “cold” cancer, often with […]